On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
Professor Peter Schmid, FRCP, MD, PhD, Leisha A. Emens, MD, PhD, and Heather L. McArthur, MD, MPH, prepared useful practice aids pertaining to the role of immunotherapy in triple-negative breast cancer for this CME/MOC/CNE activity titled, "On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum." For the full presentation, monograph, complete CME/MOC/CNE information, and to apply for credit, please visit us at http://bit.ly/34aGu95. CME/MOC/CNE credit will be available until December 29, 2020.
How can immunotherapy be used to treat metastatic breast cancer? Ian Krop, MD, PhD, discusses the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 and hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
In this presentation, I discuss a new standard of treatment in cancers which is immunotherapy. I also discuss the few cancers for which it has been approved.
How can immunotherapy be used to treat metastatic breast cancer? Ian Krop, MD, PhD, discusses the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 and hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
In this presentation, I discuss a new standard of treatment in cancers which is immunotherapy. I also discuss the few cancers for which it has been approved.
ADC’s - What Everyone with MBC Should Know about Antibody Drug Conjugatesbkling
Antibody drug conjugates (ADC’s), a novel class of anticancer agents, have been around for decades but recently great strides have been made in metastatic breast cancer. Next generation ADC’s, sometimes referred to as ' Trojan Horses' have shown promising efficacy in all subtypes of MBC. Join Dr. Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, and partner with Tennessee Oncology PLCC, as she presents an overview of ADC’s, biomarkers and clinical mapping, current treatment options, as well as the promising trials to keep an eye on. There will be time for your questions throughout the presentation.
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancerbkling
In recent years, researchers have been looking into using a class of drugs called PARP inhibitors to prevent the progression and recurrence of ovarian cancer. Dr. Kathleen Moore of Stephenson Cancer Center, Principal Investigator of the SOLO-1 trial, explains how the results of this trial may affect ovarian cancer patients and where research on ovarian cancer treatment is headed next.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
this slide contain information about antibody mediated anti-cancer therapy like antibody drug conjugates (ADC), Bispecific monoclonal antibody, Immuno-checkpoint therapy, biomarkers, mechanism of action of all 3 therapies, approved drugs of each category
Brendon Stiles, MD, prepared useful practice aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3dtEC0y. CME/MOC credit will be available until June 9, 2021.
Brendon Stiles, MD, Jamie E. Chaft, MD, and David H. Harpole Jr., MD, prepared useful Practice Aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2UnPFkF. CME/MOC credit will be available until June 24, 2021.
ADC’s - What Everyone with MBC Should Know about Antibody Drug Conjugatesbkling
Antibody drug conjugates (ADC’s), a novel class of anticancer agents, have been around for decades but recently great strides have been made in metastatic breast cancer. Next generation ADC’s, sometimes referred to as ' Trojan Horses' have shown promising efficacy in all subtypes of MBC. Join Dr. Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, and partner with Tennessee Oncology PLCC, as she presents an overview of ADC’s, biomarkers and clinical mapping, current treatment options, as well as the promising trials to keep an eye on. There will be time for your questions throughout the presentation.
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancerbkling
In recent years, researchers have been looking into using a class of drugs called PARP inhibitors to prevent the progression and recurrence of ovarian cancer. Dr. Kathleen Moore of Stephenson Cancer Center, Principal Investigator of the SOLO-1 trial, explains how the results of this trial may affect ovarian cancer patients and where research on ovarian cancer treatment is headed next.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
this slide contain information about antibody mediated anti-cancer therapy like antibody drug conjugates (ADC), Bispecific monoclonal antibody, Immuno-checkpoint therapy, biomarkers, mechanism of action of all 3 therapies, approved drugs of each category
Similar to On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
Brendon Stiles, MD, prepared useful practice aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3dtEC0y. CME/MOC credit will be available until June 9, 2021.
Brendon Stiles, MD, Jamie E. Chaft, MD, and David H. Harpole Jr., MD, prepared useful Practice Aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2UnPFkF. CME/MOC credit will be available until June 24, 2021.
Robert Anders, MD, PhD, Julie R. Brahmer, MD, MSc, and Christopher D. Gocke, MD, prepared useful Practice Aids pertaining to immunotherapy and biomarker testing for this CME/MOC/CC activity titled "Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era." For the full presentation, monograph, complete CME/MOC/CC information, and to apply for credit, please visit us at http://bit.ly/2L7zlSy. CME/MOC/CC credit will be available until May 2, 2020.
Roy H. Decker, MD, PhD; Kristin Higgins, MD; and Jyoti D. Patel, MD, prepared useful practice aids pertaining to immunotherapies in lung cancer for this CME/MOC activity titled “NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer.” For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2mFfEWE. CME/MOC credit will be available until October 22, 2020.
Jessica Donington, MD, Natasha Leighl, MD, MMSc, FRCPC, FASCO, and Brendon Stiles, MD, prepared useful practice aids pertaining to the role of immunotherapy in lung cancer for this CME/MOC/CNE activity titled, "The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Thoracic Surgeons." For the full presentation, monograph, complete CME/MOC/CNE information, and to apply for credit, please visit us at http://bit.ly/2WibbtU. CME/MOC/CNE credit will be available until June 16, 2020.
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
Sylvia Adams, MD, medical oncologist, and associate professor at the NYU School of Medicine, discusses the latest research including the role of immunology in the treatment of triple negative metastatic breast cancer. This webinar was hosted on October 19, 2016.
Arjun Balar, MD, and Petros Grivas, MD, PhD, prepared useful practice aids pertaining to bladder cancer management for this CME activity titled "Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2GpacAq. CME credit will be available until December 30, 2019.
Marianne Davies, DNP, ACNP, AOCNP, prepared useful practice aids pertaining to cancer immunotherapy for this CNE activity titled, "Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses." For the full presentation, monograph, complete CNE information, and to apply for credit, please visit us at http://bit.ly/36bACxW. CNE credit will be available until January 26, 2021.
Naiyer Rizvi, MD, and Benny Weksler, MBA, MD, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/CE activity titled "The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care." For the full presentation, monograph, complete CME/MOC/CE information, and to apply for credit, please visit us at http://bit.ly/2KEjDL6. CME/MOC/CE credit will be available until December 5, 2019.
Immunological Checkpoints and Cancer Immunotherapyimgcommcall
Immunological Checkpoints and Cancer Immunotherapy: Review of Data and Issues of Interest for Imaging Community presented by Dr. Elad Sharon
Similar to On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum (20)
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.
Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Chair Jonathan A. Bernstein, MD, discusses chronic spontaneous urticaria in this CME activity titled “BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3P0cnvi. CME credit will be available until May 6, 2025.
More from PVI, PeerView Institute for Medical Education (20)
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
1. a
Must consist of ≥2 separate tumor cores from the primary tumor. b
Patients without pCR data for any reason or who received neoadjuvant chemotherapy not specified in the protocol were counted as non-pCR. c
PD-L1 assessed at a central laboratory using the PD-L1 IHC 22C3 pharmDx assay and measured
using the combined positive score (CPS); number of PD-L1+ tumor cells, lymphocytes, and macrophages divided by the total number of tumor cells x100; PD-L1+ = CPS ≥1. d
1 patient from sepsis and multiple organ dysfunction syndrome; 1 patient from pneumonitis. e
1 patient from septic shock.
f
1 patient from pulmonary embolism.
CPS: combined positive score; ECOG PS: Eastern Cooperative Oncology Group performance status; EFS: event-free survival; IA: interim analysis; IHC: immunohistochemistry; ITT: intent to treat; pCR: pathologic complete response; PD-L1: programmed death ligand-1; Q3W: every 3 weeks; QW: every week;
TIL: tumor-infiltrating lymphocyte; TNBC: triple-negative breast cancer; TRAE: treatment-related adverse effect.
1. Schmid P et al. AnnOncol. 2019;30(suppl 5):v851-v934.
Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of
Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
PEMBROLIZUMAB AS NEOADJUVANT/ADJUVANT
THERAPY FOR EARLY TRIPLE-NEGATIVE BREAST CANCER
A Trial Overview
PRACTICE AID
KEYNOTE-5221
The first prospective, randomized, placebo-
controlled, phase 3 trial of pembrolizumab in
early TNBC in the neoadjuvant/adjuvant setting
• Age ≥18 y
• Newly diagnosed TNBC
of either T1c N1-2 or
T2-4 N0-2
• ECOG PS 0-1
• Tissue sample for PD-L1
assessmenta
Patients
Pembrolizumab
200 mg Q3W
Placebo
2:1 randomization stratified by nodal status, tumor size, and
carboplatin schedule (QW vs Q3W)
Neoadjuvant Phase Adjuvant Phase
Neoadjuvant
Treatment 1
(cycles 1-4; 12 wk)
Neoadjuvant
Treatment 2
(cycles 5-8; 12 wk)
Adjuvant
Treatment
(cycles 1-9; 27 wk)
Carboplatin
+ paclitaxel
Carboplatin dose: AUC 5 Q3W or AUC 1.5 QW; paclitaxel dose: 80 mg/m2
QW; doxorubicin dose:60 mg/m2
Q3W; epirubicin dose: 90 mg/m2
Q3W; cyclophosphamide dose: 600 mg/m2
Q3W
Doxorubicin/epirubicin
+ cyclophosphamide
Carboplatin
+ paclitaxel
Doxorubicin/epirubicin
+ cyclophosphamide
S
U
R
G
E
R
Y
Pembrolizumab
200 mg Q3W
Placebo
Including radiation
therapy as indicated
Pembro
vs Placebo
Endpoints
Co-primary
• pCR (ypT0/Tis ypN0)
in ITTb
• EFS in ITT
Secondary
• pCR as per ypT0
ypN0 and ypT0/Tis
• OS
• pCR, EFS,b
and
OS in PD-L1+c
• Safety
Exploratory
• Residual cancer burden,
EFS by pCR, and pCR
and EFS by TILs
pCR at IA1
Primary Endpoint (ypT0/Tis ypN0) Secondary Endpoint (ypT0 ypN0) Secondary Endpoint (ypT0/Tis) PD-L1+ (ypT0/Tis ypN0) PD-L1- (ypT0/Tis ypN0)
64.8%
51.2%
13.6 (5.4-21.8)
P = .00055
59.9%
45.3%
14.5 (6.2-22.7)
68.6%
53.7%
14.8 (6.8-23.0)
68.9%
54.9%
45.3%
30.3%
14.2 (5.3-23.1) 18.3 (-3.3-36.8)
PembroPlacebo
EFS at IA2
18-mo Rate
91.3%
85.3%
PembroPlacebo
Therapy Results
HR
(95% CI)
Events, %
Pembro 7.4
0.63
(0.43-0.93)
Placebo 11.8
TRAE, %
Pembro
(n = 781)
Chemo
(n = 389)
Any grade 99.0 99.7
Grade 3-5 76.8 72.2
Led to death 0.3d 0.3e
Led to
discontinuation
of any drug
23.3 12.3
n = 784
n = 390
TRAEs in Neoadjuvant Phase
IA2
TRAEs in Adjuvant Phase
IA2
TRAE, %
Pembro
(n = 547)
Chemo
(n = 314)
Any grade 48.1 43.0
Grade 3-5 5.7 1.9
Led to death 0.2f 0
Led to
discontinuation
of any drug
3.3 1.3
2. a
Centrally evaluated per VENTANA PD-L1 (SP142) IHC assay (double blinded for PD-L1 status); positive = ≥1%; negative = <1%. b
Radiological endpoints were investigator assessed per RECIST v1.1. c
Treatment-related deaths: autoimmune hepatitis, mucosal inflammation/death, and septic shock.
AE: adverse effect; DOR: duration of response; ECOG PS: Eastern Cooperative Oncology Group performance status; IC: tumor-infiltrating immune cell; IHC: immunohistochemistry; ITT: intent to treat; mTNBC: metastatic triple-negative breast cancer; nab-P: nab-paclitaxel; ORR: objective response rate;
PBO: placebo; PD: progressive disease; PD-L1: programmed death ligand-1; RECIST: Response Evaluation Criteria in Solid Tumors; TFI: treatment-free interval; TNBC: triple-negative breast cancer; TRAE: treatment-related adverse effect.
1. Schmid P et al. 43rd European Society for Medical Oncology Congress (ESMO 2018). Abstract LBA1_PR. 2. Schmid P et al. NEnglJMed. 2018;379:2108-2121.
Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of
Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN LOCALLY
ADVANCED/METASTATIC TRIPLE-NEGATIVE BREAST CANCER
A Trial Overview
PRACTICE AID
Primary PFS Analysis
Median PFS: ITT Median PFS: PD-L1+
7.2 mo
5.5 mo
Stratified HR = 0.80
(95% CI, 0.69-0.92)
P = .0025
7.5 mo
5.0 mo
21.3 mo
17.6 mo
25.0 mo
15.5 mo
Atezo
+nab-P
Placebo
+nab-P
ORR
56%
46%
Safety Summary
Interim OS Analysis
Median OS: ITT Median OS: PD-L1+
Atezo
+nab-P
Placebo
+nab-P
Atezo
+nab-P
Placebo
+nab-P
Stratified HR = 0.62
(95% CI, 0.49-0.78)
P < .0001
Stratified HR = 0.84
(95% CI, 0.69-1.02)
P = .0840
Stratified HR = 0.62
(95% CI, 0.45-0.86)
ITT PD-L1+
59%
43%
DOR
7.4 mo
DOR
5.6 mo
DOR
8.5 mo
DOR
5.5 mo
TRAE, %
Atezo
+ nab-P
(n = 452)
Placebo
+ nab-P
(n = 438)
Any grade 96 94
Grade 3/4 40 30
Grade 5c
1 <1
All-Cause
AEs, %
Atezo
+ nab-P
(n = 452)
Placebo
+ nab-P
(n = 438)
Any grade 99 98
Grade 3/4 49 42
Grade 5 1 1
Any-Grade
Serious AEs,
%
Atezo
+ nab-P
(n = 452)
Placebo
+ nab-P
(n = 438)
Regardless
of attribution
23 18
TRAEs 12 7
Safety-Evaluable Population
Until RECIST v1.1
PD or toxicity
IMpassion1301,2
The first prospective, randomized, placebo-controlled, phase 3 trial to demonstrate a benefit with first-line immunotherapy in mTNBC
• Metastatic or inoperable
locally advanced TNBC
• No prior therapy for
advanced TNBC (prior
chemo in the curative
setting, including taxanes,
allowed if TFI ≥12 mo)
• ECOG PS 0-1
Patients Atezolizumab 840 mg on d 1 and 15 of 28-d cycle
+ nab-paclitaxel 100 mg/m2
IV on d 1, 8, and 15 of 28-d cycle
Placebo IV on d 1 and 15 of 28-d cycle
+ nab-paclitaxel 100 mg/m2
on d 1, 8, and 15 of 28-d cycle
1:1 randomization stratified by prior taxane use, liver
metastases, and PD-L1 status on IC (≥1% vs <1%)a
Double-blind; no crossover permitted
Atezo
+ nab-P
vs PBO
+ nab-
Endpoints
Co-primary
• PFS and OS in the
ITT and PD-L1+
populationsb
Key Secondary
• ORR, DOR, and
safety
n = 451
n = 451
3. IMMUNO-ONCOLOGY 101
Harnessing the Immune System in the
Treatment of Triple-Negative Breast Cancer
PRACTICE AID
Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most
of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
Without
Immunotherapy
With
Immunotherapy
MHC
Antigen
TCR
PD-1
PD-L1
Anti–
PD-L1
Anti–
PD-1
Tumor
cell
Tumor escape
Inactivation
of T Cell
Activation
of T Cell
Elimination of
tumor cells
Without
Immunotherapy
With
Immunotherapy
MHC CD80/86
CTLA-4
Anti–
CTLA-4
antibody
APC
Antigen
TCR
Inactivation
of T Cell
Activation
of T Cell
Tumor escape Elimination of
tumor cells
Immune Checkpoint Inhibition in the Treatment of Cancer1
Immune
checkpoints
Proteins on T cells or cancer cells that need to be
activated/inactivated to start/stop an immune response
Examples include PD-1, PD-L1, CTLA-4
Serve as “brakes” that help keep immune responses in
check; can prevent T-cell response against cancer cells
Can be blocked by immune checkpoint inhibitors
The “brakes” on the immune system are released
and T cells are able to attack and kill cancer cells
PD-1/PD-L1 Checkpoint Inhibition2
CTLA-4 Checkpoint Inhibition2
CTLA-4 is a negative
regulator of
costimulation required
for activation of an
antitumor T cell in a
lymph node upon
recognition of
tumor antigen
PD-1 pathway inhibits
signaling downstream of TCR:
TCR triggered by antigen
presented by tumor cell à
negative regulatory
receptor PD-1 expressed à
PD-L1 reactively expressed à
PD-L1 binds to PD-1
Tumor microenvironment Lymphoid tissue
Anti–PD-1
or anti–PD-L1
monoclonal
antibodies
block the
interaction and
negative
regulation
Anti–CTLA-4
monoclonal
antibodies block
negative
regulation by
CTLA-4
T cell inactivated
Tumor escape
T cell activated
Tumor attack
T cell inactivated
Tumor escape
T cell activated
Tumor attack
STOP GO STOP GO
4. IMMUNO-ONCOLOGY 101
Harnessing the Immune System in the
Treatment of Triple-Negative Breast Cancer
PRACTICE AID
APC: antigen-presenting cell; CD: cluster of differentiation; CTLA-4: cytotoxic T-lymphocyte–associated protein 4; MHC: major histocompatibility complex; PD-1: programmed cell death protein 1;
PD-L1: programmed death ligand 1; TCR: T-cell receptor; TIL: tumor-infiltrating lymphocyte; TNBC: triple-negative breast cancer.
1. Ribas A, Wolchock JD. Science. 2018;359:1350-1355. 2. Adapted from: Soularue E et al. Gut. 2018;67:2056-2067. 3. de la Cruz-Merino et al. Clin Trans Oncol. 2019;21:117-125. 4. Vikas P et al. Cancer Manag Res.
2018;10:6823-6833. 5. Tecentriq (atezolizumab) Prescribing Information. https://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed November 19, 2019. 6. https://www.fda.gov/Drugs/
InformationOnDrugs/ApprovedDrugs/ucm633065.htm. Accessed November 19, 2019.
Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most
of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
Rationale for Immunotherapy in TNBC3,4
FDA Approval of
Immunotherapy in TNBC5,6
First approval in breast cancer
FDA granted accelerated approval
to atezolizumab in combination with
nab-paclitaxel for adult patients with
unresectable locally advanced or
metastatic TNBC whose tumors
express PD-L1 (PD-L1–stained,
tumor-infiltrating immune cells of
any intensity covering ≥1% of the
tumor area), as determined by an
FDA-approved test
More to come!
Immune Checkpoint Inhibitors
Under Investigation in TNBC
Anti–PD-1 inhibitors:
Pembrolizumab
Nivolumab
Anti–PD-L1 inhibitors:
Atezolizumab
Durvalumab
Avelumab
Anti–CTLA-4 inhibitors:
Ipilimumab
Tremelimumab
TNBC tumors with a highly invasive
characteristic express a large amount of PD-L1
and a high degree of TILs compared with other
subtypes of breast cancer
Implicates immunogenic nature of TNBC
Rationale for testing/use of immunotherapies
in TNBC
More aggressive forms of breast cancer have some
degree of host immunity, but it appears to decrease
as the tumors progress and become more resistant
(eg, advanced, heavily pretreated TNBC)
Reduction in body’s immune response to the cancer
Immunotherapy may be more effective in earlier
stages of TNBC
Rationale for testing/use of immunotherapies
in neoadjuvant or adjuvant settings
Multimodal therapy may enhance the activity of
immunotherapies in TNBC and other subtypes
of breast cancer
Combination or sequential strategies with
chemotherapies, targeted therapies, other
immunotherapies with nonredundant
mechanisms of action, vaccines, surgery,
radiation, and cryotherapy are being explored
5. Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of
Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
SELECTION OF KEY IMMUNO-ONCOLOGY
CLINICAL TRIALS IN TRIPLE-NEGATIVE BREAST CANCER1
PRACTICE AID
Atezolizumab + nab-paclitaxel atezolizumab +
AC surgery atezolizumab
vs
placebo + nab-paclitaxel placebo + AC surgery
NCT03197935 IMpassion031
Phase 3
Anti–PD-L1
Atezolizumab + paclitaxel + carboplatin
atezolizumab + (AC or EC) surgery atezolizumab
vs
placebo + paclitaxel + carboplatin placebo + (AC or EC)
surgery placebo
NCT03281954 GBG 96-GeparDouze
Phase 3
Anti–PD-L1
Atezolizumab + nab-paclitaxel + carboplatin
surgery AC or EC or FEC
vs
nab-paclitaxel + carboplatin surgery AC or EC or FEC
NCT02620280 NeoTRIPaPDL1
Phase 3
Anti–PD-L1
NCT03036488a KEYNOTE-522
Phase 3
Anti–PD-1
Durvalumab durvalumab + nab-paclitaxel
durvalumab + EC surgery
vs
placebo placebo + nab-paclitaxel placebo + EC surgery
NCT02685059 GeparNuevo
Phase 2
Anti–PD-L1
Pembrolizumab + nab-paclitaxel
pembrolizumab + EC surgery
NCT03289819 NIB
Phase 2
Anti–PD-1
Olaparib durvalumab + olaparib surgery
NCT03594396
Phase
1/2
Anti–PD-L1
Pembrolizumab + radiotherapy boost surgery
NCT03366844 Anti–PD-1
Phase
1/2
Nivolumab surgery
vs
nivolumab + doxorubicin surgery
NCT03815890 BELLINI
Phase 2
Anti–PD-1
Nivolumab + ipilimumab
core biopsy/cryoablation surgery nivolumab
vs
surgery
NCT03546686
Phase 2
Anti–PD-1 + anti–CTLA-4
Neoadjuvant Setting
Pembrolizumab + paclitaxel + carboplatin
pembrolizumab + (AC or EC) surgery pembrolizumab
vs
placebo + paclitaxel + carboplatin placebo + (AC or EC)
surgery placebo
6. Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of
Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
SELECTION OF KEY IMMUNO-ONCOLOGY
CLINICAL TRIALS IN TRIPLE-NEGATIVE BREAST CANCER1
PRACTICE AID
Pembrolizumab + radiotherapy
vs
observation + radiotherapy
(for residual disease after neoadjuvant chemo and surgery)
NCT02954874 SWOG-S1418
Phase 3
Anti–PD-1
Avelumab
vs
observation
(after surgery, neo- or adjuvant chemo, and radiotherapy if indicated)
NCT02926196 A-Brave
Phase 3
Anti–PD-L1
Atezolizumab + paclitaxel →
atezolizumab + (AC or EC) → atezolizumab
vs
paclitaxel → AC or EC
NCT03498716 IMpassion030
Phase 3
Anti–PD-L1
Nivolumab
vs
capecitabine
vs
nivolumab + capecitabine
(for residual disease after neoadjuvant chemo and surgery)
NCT03487666 OXEL
Phase 2
Anti–PD-1
Adjuvant Setting
Nivolumab + ipilimumab + radiotherapy
vs
capecitabine + radiotherapy
(for residual disease after neoadjuvant chemo and surgery)
NCT03818685
BreastImmune03
Phase 2
Anti–PD-1 + anti–CTLA-4
Atezolizumab + capecitabine
vs
capecitabine
(for residual disease after neoadjuvant chemo and surgery)
NCT03756298
Phase 2
Anti–PD-1
7. Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of
Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
SELECTION OF KEY IMMUNO-ONCOLOGY
CLINICAL TRIALS IN TRIPLE-NEGATIVE BREAST CANCER1
PRACTICE AID
Atezolizumab + nab-paclitaxel
vs
placebo + nab-paclitaxel
NCT02425891 IMpassion130
Phase 3
Anti–PD-L1
Atezolizumab + paclitaxel
vs
placebo + paclitaxel
NCT03125902 IMpassion131
Phase 3
Anti–PD-L1
Pembrolizumab + [nab-paclitaxel or
paclitaxel or (gemcitabine + carboplatin)]
vs
placebo + [nab-paclitaxel or paclitaxel or (gemcitabine + carboplatin)]
NCT02819518 KEYNOTE-355
Phase 3
Anti–PD-1
Metastatic/Advanced Setting
Pembrolizumab
NCT02447003 KEYNOTE-086
Phase 2
Anti–PD-1
1st line
1st line
1st line
Durvalumab + tremelimumab → durvalumab
NCT02536794
Phase 2
Anti–PD-L1 + anti–CTLA-4
1st line 1st line
Atezolizumab +
[(gemcitabine + carboplatin) or capecitabine]
vs
placebo + [(gemcitabine + carboplatin) or capecitabine]
NCT03371017 IMpassion132
Phase 3
Anti–PD-L1
1st line
Pembrolizumab
vs
capecitabine or eribulin or gemcitabine or vinorelbine
NCT02555657 KEYNOTE-119
Phase 3
Anti–PD-1
≥2nd line
Pembrolizumab + doxorubicin → pembrolizumab
NCT02648477
Phase 2
Anti–PD-1
Pembrolizumab + nab-paclitaxel
NCT02752685
Phase 2
Anti–PD-1
1st line 1st line
Pembrolizumab + carboplatin + gemcitabine
vs
carboplatin + gemcitabine
NCT02755272
Phase 2
Anti–PD-1
Pembrolizumab + cyclophosphamide
NCT02768701
Phase 2
Anti–PD-1
1st line 1st line
8. a
Continued in adjuvant setting.
1. https://clinicaltrials.gov. November 26, 2019.
AC: doxorubicin + cyclophosphamide; chemo: chemotherapy; CTLA-4: cytotoxic T-lymphocyte–associated protein 4; EC: epirubicin + cyclophosphamide; FEC: fluorouracil + epirubicin + cyclophosphamide; PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1.
Access the activity,“On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of
Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum,”at PeerView.com/PMD40.
SELECTION OF KEY IMMUNO-ONCOLOGY
CLINICAL TRIALS IN TRIPLE-NEGATIVE BREAST CANCER1
PRACTICE AID
Olaparib → durvalumab + olaparib
NCT03801369
Phase 2
Anti–PD-1
Pembrolizumab + carboplatin + nab-paclitaxel
NCT03121352
Phase 2
Anti–PD-1
Pembrolizumab + radiotherapy
NCT02730130
Phase 2
Anti–PD-1
Metastatic/Advanced Setting (Cont’d)
Nivolumab + romidepsin + cisplatin
NCT02393794
Phase
1/2
Anti–PD-1
1st/2nd line
1st-3rd line
≥2nd line
Pembrolizumab + eribulin mesylate
NCT02513472 ENHANCE-1
Anti–PD-L1
≥1st line 1st-3rd line
Atezolizumab + cobimetinib + paclitaxel
vs
atezolizumab + cobimetinib + nab-paclitaxel
vs
cobimetinib + paclitaxel
vs
placebo + paclitaxel
NCT02322814
Phase 2
Anti–PD-L1
1st line
Pembrolizumab + lenvatinib
NCT03797326 LEAP-005
Phase 2
Anti–PD-1
≥2nd line
Durvalumab + paclitaxel → durvalumab
NCT02628132
Anti–PD-1
≥2nd line
Radiotherapy → nivolumab
vs
doxorubicin → nivolumab
vs
cisplatin → nivolumab
vs
cyclophosphamide → nivolumab
vs
nivolumab
NCT02499367 TONIC
Phase 2
Anti–PD-1
2nd-4th line
Phase
1/2
Phase
1/2